On December 3, 2024, Fosun Pharma announced that its subsidiary, Eucure Biopharma, has independently developed Hansizhuang® (sruvelizumab injection) which has been approved by the National Medical Products Administration for the treatment of unresectable locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with negative EGFR gene mutation and ALK negativity. This approval will enhance the market competitiveness of the drug and provide patients with more treatment options. Hansizhuang® is an innovative anti-PD-1 monoclonal antibody independently developed by Fosun Pharma, which has been approved for multiple indications in China and has received positive evaluation from the European Union. By October 2024, Fosun Pharma has invested approximately 2.868 billion yuan in the research and development of this drug. According to IQVIA data...Show More

On December 3, 2024, Fosun Pharma announced that its subsidiary, Eucure Biopharma, has independently developed Hansizhuang® (sruvelizumab injection) which has been approved by the National Medical Products Administration for the treatment of unresectable locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with negative EGFR gene mutation and ALK negativity. This approval will enhance the market competitiveness of the drug and provide patients with more treatment options. Hansizhuang® is an innovative anti-PD-1 monoclonal antibody independently developed by Fosun Pharma, which has been approved for multiple indications in China and has received positive evaluation from the European Union. By October 2024, Fosun Pharma has invested approximately 2.868 billion yuan in the research and development of this drug. According to IQVIA data, the global sales of PD-1 monoclonal antibody drugs reached approximately 39.9 billion US dollars in 2023, with sales in the Chinese market amounting to about 8.1 billion yuan. Although the approval of the new indication enhances market competitiveness, the sales performance of the drug after its launch still carries uncertainty due to factors such as market demand and competitive environment. Investors need to be aware of the associated risks.